|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
351.04/-0.38
|
Enterprise Value
1.24M
|
Balance Sheet |
Book Value Per Share
-64.53
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
0
|
Operating Revenue Per Share
--
|
Industry Comparison
|
||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 18:45 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includesSLS-002, SLS-005, SLS-004, SLS-007, and SLS-009. |